In DN, hyperglycemia-induced COX-2 overexpression in podocytes contributes to proteinuria, mesangial expansion, and podocyte foot process effacement, changes that are attenuated by RAAS inhibition or COX-2 blockade [91,92,93]. The gene discussed is PTGS2; the disease is Hyperglycemia.